Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect Study of a New Nurandociguat Tablet Formulation
NCT07722585Phase 1Completed
- Sponsor
- Bayer
- Start
- Jul 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BAY3283142 in chronic kidney disease (CKD) (7 arms), sponsored by Bayer. Primary endpoints: Maximum observed concentration, Area under the concentration time curve and 2 more. Started Jul 2026; status: completed.
02
Drugs
BAY3283142
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT07722585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07722585.